Francis, CEO of Teva Pharmaceuticals: Despite growth in the branded drug business, the generic drug business will continue to grow and remain profitable due to the advancement of biosimilar drug pipelines. The newly launched schizophrenia drug Weltruza will not generate significant revenue until the second half of 2027, which will be in an advantageous position. Despite the impact of the US Inflation Reduction Act on its Austedo drug, Teva Pharmaceuticals plans to achieve growth in 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.